2018-2022年美国耐药实验室网络:携带多重碳青霉烯酶基因的CRE与CRPA特征分析
CRE中多重碳青霉烯酶基因阳性(MCP)占1%(611株),CRPA中MCP占31株;MCP-CRE以blaKPC/blaNDM为主(47%),MCP-CRPA以blaVIM/blaIMP为主(42%)。MCP-CRE对美罗培南耐药比例(97%)高于单酶阳性CRE(79%)和非产酶CRE(13%)。
要点
- CRE中MCP占1%,CRPA中MCP仅31株,但MCP-CRE数量从2018年1%升至2022年3%。
- MCP-CRE最常见基因组合为blaKPC/blaNDM(47%),MCP-CRPA为blaVIM/blaIMP(42%)。
- MCP-CRE美罗培南耐药率97%,高于单酶CRE的79%和非产酶CRE的13%。
核心结论
- MCP菌株在总碳青霉烯酶阳性菌中占比较小,但需持续监测和进一步研究。
研究设计与样本
- 基于美国耐药实验室网络2018-2022年收集的临床CRE和CRPA分离株,由公共卫生实验室开展抗菌药物敏感性试验和5种靶向碳青霉烯酶基因检测。
主要发现
- MCP-CRE中Enterobacter spp.和E. coli频率(18%和15%;n=109和n=88)略高于SCP-CRE中对应菌种(13%和13%;n=3653和n=3471)。
- MCP-CRE数量从2018年54/5105(1%)增至2022年223/6994(3%)。
- 54490株CRPA中,SCP为1249株(2%),MCP为31株;MCP-CRPA最常见携带blaVIM/blaIMP(n=13,42%)。
- MCP-CRE中对美罗培南耐药比例为97%(n=330),高于SCP-CRE的79%(n=11227)和non-CP的13%(n=2683)。
关键数值与推荐
- MCP-CRE中blaKPC/blaNDM占47%(285/611),MCP-CRPA中blaVIM/blaIMP占42%(13/31)。
- MCP-CRE美罗培南耐药率97%(330株),SCP-CRE为79%(11227株),non-CP为13%(2683株)。
- MCP-CRE检出比例从2018年1%(54/5105)升至2022年3%(223/6994)。
临床怎么用
- 临床实验室应对CRE和CRPA开展碳青霉烯酶基因检测,以识别多重碳青霉烯酶基因共存的菌株。
- MCP-CRE对美罗培南耐药率极高,提示需关注此类难治性感染的治疗选择。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are significant public health threats, particularly when harboring carbapenemases. Literature describing the frequencies and phenotypic and genotypic characteristics of isolates harboring multiple carbapenemase genes is limited. Using data collected from the Antimicrobial Resistance Laboratory Network (AR Lab Network) in 2018-2022, we describe CRE and CRPA isolates that harbor multiple acquired carbapenemase genes. Clinical laboratories submitted CRE and CRPA isolates to AR Lab Network public health laboratories for additional characterization that included antimicrobial susceptibility testing and detection of five targeted carbapenemase genes. Isolates were classified as non-carbapenemase producing (non-CP) when negative for carbapenemase production and all targeted carbapenemase genes, or positive for a single-CP (SCP) or multiple-carbapenemase (MCP) targeted gene. Among 79,799 CREs tested, 27,599 (35%) were SCP and 611 (1%) were MCP. MCP-CRE most often carried blaKPC/blaNDM (n = 285, 47%). Both SCP-CRE and MCP-CRE were most commonly Klebsiella spp. Enterobacter spp. and Escherichia coli isolates harboring MCP were detected at slightly higher frequencies (18% and 15%; n = 109 and n = 88, respectively) than Enterobacter spp. and Escherichia coli isolates harboring SCP (13% and 13%; n = 3,653 and 3,471, respectively). The number of MCP-CRE detected increased from 54 of 5,105 (1%) in 2018 to 223 of 6,994 (3%) in 2022. Among 54,490 CRPA tested, 2% (n = 1,249) were SCP and 31 were MCP. MCP-CRPA most often carried blaVIM/blaIMP (n = 13, 42%). A higher proportion of MCP-CRE (97%, n = 330) isolates were categorized as resistant to meropenem, compared to SCP-CRE (79%; n = 11,227) and non-CP (13%; n = 2,683). Although MCP organisms represent a small proportion of total CP detected in the AR Lab Network, there is a need for continued monitoring and additional research.IMPORTANCECarbapenemase-producing organisms are of significant clinical and public health concerns, and rapid detection and containment of such threats are vital to preventing their spread. In this article, we used a collection of over 130,000 contemporary isolates to evaluate frequencies and phenotypic and genotypic properties of CRE and CRPA isolates harboring multiple carbapenemase genes across the United States, from 2018 to 2022. Of note, 95% and 100% of CRE and CRPA isolates co-harbored at least one metallo-β-lactamase gene, respectively, indicating a high proportion of isolates originating from patients with difficult-to-treat infections. Both clinical and public health professionals across the nation can use these data and key findings to better understand the molecular landscape of these isolates. Timely detection and control of these organisms are essential to combating the spread of antibiotic resistance and ensuring the availability of effective treatment options for patients.
引用
- Sabour S, Harrington KRV, Martinson E, et al. Characterization of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa carrying multiple carbapenemase genes-Antimicrobial Resistance Laboratory Network, 2018-2022. J Clin Microbiol. 2024. PMID: 39565121. doi:10.1128/jcm.01220-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。